Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025811) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025811 International Application No.: PCT/GB2018/052222
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
C07K 7/08 (2006.01) ,A61K 47/60 (2017.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
08
having 12 to 20 amino acids
[IPC code unknown for A61K 47/60]
Applicants:
BICYCLETX LIMITED [GB/GB]; Building 900 Babraham Research Campus Cambridge CB22 3AT, GB
Inventors:
CHEN, Liuhong; GB
LANI, Rachid; GB
MCDONNELL, Kevin; GB
MUDD, Gemma; GB
PARK, Peter; GB
Agent:
GIBSON, Mark; GB
AITKEN, Elizabeth; GB
Priority Data:
1712589.904.08.2017GB
1802934.823.02.2018GB
1805850.309.04.2018GB
Title (EN) BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137
(FR) LIGANDS PEPTIDIQUES BICYCLIQUES SPÉCIFIQUES DE CD137
Abstract:
(EN) The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137.The invention also includes drug conjugates comprising said peptides,conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
(FR) Cette invention concerne des polypeptides qui sont liés par covalence à des échafaudages moléculaires de façon que deux boucles peptidiques ou plus soient sous-tendues entre des points d'attachement à l'échafaudage. En particulier, l'invention concerne des peptides qui sont des lieurs à haute affinité de CD137. Des conjugués médicamenteux comprenant lesdits peptides, conjugués à un ou plusieurs groupes effecteurs et/ou fonctionnels, des compositions pharmaceutiques comprenant lesdits ligands peptidiques et des conjugués médicamenteux et leur utilisation dans la prévention, la suppression ou le traitement d'une maladie ou d'un trouble médié par CD137 sont en outre décrits.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)